Atossa Genetics, Inc. to Present at FSX San Francisco Investor Conference

SEATTLE, WA--(Marketwired - April 23, 2013) -

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Kyle Guse, CFO and General Counsel, will present the Company’s business model, products and services, and investment thesis at the FSX San Francisco Conference at the Ritz Carlton Hotel in San Francisco on Thursday, April 25, 2013, beginning at 2:40 pm Pacific Time.

“The national rollout of our ForeCYTE Breast Health Test continues to advance,” Mr. Guse stated. “We are pleased by the growing interest and enthusiastic response we are getting from the medical community and patients. I look forward to providing an update on our marketing efforts and other corporate activities at the FSX conference.”

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

In addition to the ForeCYTE Breast Health Test, Atossa markets the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a “liquid biopsy” for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

For additional information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with marketing plans, actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa’s ability to continue to manufacture and sell its products, the efficacy of Atossa’s products and services, the market demand for and acceptance of Atossa’s products and services, performance of distributors and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed January 28, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: breast cancer prevention ForeCYTE ArgusCYTE ductal carcinoma in situ intraductal therapy